What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The QUAZAR trial demonstrated that oral azacitidine significantly improves overall survival (24.7 months vs. 14.8 months for placebo) and relapse-free survival (10.2 months vs. 4.8 months for placebo) in adults with AML who cannot undergo stem cell transplantation. This evidence is derived from a Phase 3 RCT, which supports a clear clinical advantage over standard care.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for oral azacitidine are within NICE’s acceptable range for end-of-life treatments, with ICERs slightly above £30,000 per QALY gained. The committee found the model robust after addressing uncertainties, supporting its marginal cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee acknowledged that oral azacitidine improves quality of life by allowing treatment at home, reducing hospital visits, and potentially extending life expectancy. However, specific HRQoL data post-relapse were not fully captured in the QUAZAR trial, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Oral azacitidine has a favorable safety profile, with adverse events primarily being mild to moderate. The committee noted that serious adverse events were rare, indicating good tolerability compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The main comparator was placebo plus best supportive care, which is appropriate for the population studied. However, the exclusion of low dose cytarabine and subcutaneous azacitidine as comparators raised concerns about the completeness of the evidence base.
Is the population defined the way payers need it? — Patient Population and Subgroups
The QUAZAR trial included a representative population of adults with AML in complete remission who cannot undergo stem cell transplantation. The committee noted that the trial’s EU-subgroup data were generalizable to UK clinical practice.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Oral azacitidine can be integrated into existing care pathways with minimal disruption, as it allows for home administration and does not require new infrastructure or extensive training for healthcare providers.
Are the wider system costs understood? — Resource Use and Cost Implications
The implementation of oral azacitidine is expected to have a manageable budget impact, as it provides a new treatment option for a population with limited alternatives, potentially leading to cost savings in hospitalizations.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a well-conducted Phase 3 RCT with low risk of bias and robust data. The committee found the trial’s design and execution to be strong, supporting the reliability of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding long-term benefits and the impact of treatment effect waning, the overall context of unmet need and the potential to address equity issues in treatment access support a moderate rating.
